Canakinumab for the Treatment of Postprandial Hypoglycemia — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Canakinumab for the Treatment of Postprandial Hypoglycemia — Stella

Recruiting

Back to Postprandial Hypoglycemia trials

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(2 sites)

Switzerland

University Hospital Basel, Division of Endocrinology, Diabetes and Metabolism, Basel

Cantonal Hospital Olten, Division of Endocrinology, Olten

Key details

Phase

Large-scale testing

Sponsor

University Hospital, Basel, Switzerland

Enrollment target

~56 participants

Started

April 2023

Primary completion

May 2026

Age range

18 Years – 75 Years

Last updated January 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov